Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Centrizonal arteries and microvessels in nonalcoholic steatohepatitis.

Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD.

Am J Surg Pathol. 2011 Sep;35(9):1400-4. doi: 10.1097/PAS.0b013e3182254283.

2.

Aberrant centrizonal features in chronic hepatic venous outflow obstruction: centrilobular mimicry of portal-based disease.

Krings G, Can B, Ferrell L.

Am J Surg Pathol. 2014 Feb;38(2):205-14. doi: 10.1097/PAS.0000000000000099.

PMID:
24418854
3.

In hepatic venous outflow obstruction, alcoholic liver disease, and nonalcoholic fatty liver disease, centrilobular scars, CD34+ vessels, and keratin 7+ hepatocytes are in close proximity.

Matsukuma S, Takeo H, Utsumi Y, Sato K.

Virchows Arch. 2017 Apr;470(4):411-420. doi: 10.1007/s00428-017-2074-6. Epub 2017 Jan 23.

PMID:
28116521
4.

Central portalization correlates with fibrosis but not with risk factors for nonalcoholic steatohepatitis in steatotic chronic hepatitis C.

Lee H, Ainechi S, Dresser K, Kurian EM.

Int J Hepatol. 2014;2014:329297. doi: 10.1155/2014/329297. Epub 2014 Nov 30.

5.

Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?

Cengiz M, Candır BA, Yılmaz G, Akyol G, Ozenirler S.

World J Gastroenterol. 2013 Nov 14;19(42):7412-8. doi: 10.3748/wjg.v19.i42.7412.

6.

Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.

Ekstedt M, Franzén LE, Mathiesen UL, Kechagias S.

Scand J Gastroenterol. 2012 Jan;47(1):108-15. doi: 10.3109/00365521.2011.634024. Epub 2011 Nov 30.

PMID:
22126450
7.

Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.

Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E.

World J Gastroenterol. 2014 Sep 21;20(35):12566-73. doi: 10.3748/wjg.v20.i35.12566.

8.

[Clinical characteristics of non-alcoholic steatohepatitis (NASH) patients who progressed from F3 stage fibrosis to cirrhotic NASH].

Kawanaka M, Oka T, Urata N, Kimura T, Nakamura J, Goto D, Yamato R, Nishino K, Suehiro M, Kawamoto H, Yamada G.

Nihon Shokakibyo Gakkai Zasshi. 2012 Dec;109(12):2042-8. Japanese.

PMID:
23221052
9.

Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.

Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD.

Gastroenterology. 2007 Jul;133(1):80-90. Epub 2007 May 16.

PMID:
17631134
10.

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.

Harrison SA, Torgerson S, Hayashi PH.

Am J Gastroenterol. 2003 Sep;98(9):2042-7.

PMID:
14499785
11.

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network..

Hepatology. 2010 Sep;52(3):913-24. doi: 10.1002/hep.23784.

12.

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group..

Gastroenterology. 2014 Aug;147(2):377-84.e1. doi: 10.1053/j.gastro.2014.04.046. Epub 2014 May 9.

PMID:
24818764
13.

The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.

Shalhub S, Parsee A, Gallagher SF, Haines KL, Willkomm C, Brantley SG, Pinkas H, Saff-Koche L, Murr MM.

Obes Surg. 2004 Jan;14(1):54-9.

PMID:
14980034
14.

Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).

Kalra N, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, Singh P, Khandelwal N.

Ann Hepatol. 2009 Jan-Mar;8(1):21-5.

PMID:
19221529
15.

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).

Verma S, Jensen D, Hart J, Mohanty SR.

Liver Int. 2013 Oct;33(9):1398-405. doi: 10.1111/liv.12226. Epub 2013 Jun 13.

PMID:
23763360
16.

Roles of hepatic progenitor cells activation, ductular reaction proliferation and Notch signaling in morbid obesity.

Liew PL, Wang W, Lee YC, Huang MT, Lee WJ.

Hepatogastroenterology. 2012 Sep;59(118):1921-7. doi: 10.5754/hge10861.

PMID:
22819913
17.

Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men.

Kim JK, Chon NR, Lim HC, Lee KS, Han KH, Chon CY, Park YN, Paik YH.

J Gastroenterol Hepatol. 2012 Jan;27(1):142-8. doi: 10.1111/j.1440-1746.2011.06895.x.

PMID:
21883454
18.

Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.

Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K.

J Gastroenterol Hepatol. 2009 Feb;24(2):248-54. doi: 10.1111/j.1440-1746.2008.05640.x. Epub 2008 Nov 20.

PMID:
19032450
19.

Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension.

Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R.

Am J Gastroenterol. 2010 Feb;105(2):336-44. doi: 10.1038/ajg.2009.587. Epub 2009 Oct 27.

PMID:
19861959
20.

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Angulo P, Keach JC, Batts KP, Lindor KD.

Hepatology. 1999 Dec;30(6):1356-62.

PMID:
10573511

Supplemental Content

Support Center